FindTrial
Sign In

Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of atherosclerosis progression assessed by IVUS (IntraVascular UltraSounds), in overweight patients with clustering risk factors

Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of atherosclerosis progression assessed by IVUS (IntraVascular UltraSounds), in overweight patients with clustering risk factors

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-003929-27-IT
Enrollment
Unknown
Registered
2005-07-15
Start date
2005-04-14
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inhibition of coronary atherosclerosis progression in overweight patients with a cluster of risk factors.

Interventions

Product Name: Rimonabant Product Code: SR141716 Pharmaceutical Form: Tablet CAS Number: 168273-06-1 Current Sponsor code: SR141716 Concentration unit: mg milligram(s) Concentration type: equal Concent

Sponsors

SANOFI-SYNTHELABO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026